University of Maryland, Baltimore (UMB) startup, Secretome Therapeutics (formerly NeoProgen), is developing a novel cell-based therapy for people who experience a heart attack and patients with advanced heart failure. The company’s technology is developed from neonatal Cardiac Progenitor Cells (nCPCs) derived from tissue discarded during lifesaving heart surgery in babies with congenital heart conditions. UMB’s leading pediatric cardiac surgeon, Sunjay Kaushal, MD, PhD, and his lab have published groundbreaking work in preclinical studies that show nCPCs appear to be superior to other cell therapies being pursued by competing academic and commercial groups for functional markers of cardiovascular disease.